Long-term clinical experience with zofenopril

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 8, 2012, Pages 973-982

  Borghi, Claudio ^a   Bacchelli, Stefano ^a   Degli Esposti, Daniela ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ACE inhibition; angiotensin converting enzyme inhibition; coronary artery disease; myocardial infarction; SMILE; zofenopril

Indexed keywords

ACETYLSALICYLIC ACID; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; EPICAPTOPRIL; LISINOPRIL; RAMIPRIL; ZOFENOPRIL;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTIOXIDANT ACTIVITY; BLOOD CLOT LYSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTENSION; INFARCTION; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR ASSIST DEVICE; METABOLIC SYNDROME X; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; POST TREATMENT SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CAPTOPRIL; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS;

EID: 84867093434     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.81     Document Type: Review

References (37)

1. Nicholls MG, Robertson JI, Inagami T. The renin-angiotensin system in the twenty-first century. Blood Press. 10(5-6), 327-343 (2001).
2. Robertson JI, Nicholls MG. The Renin-Angiotensin System. Robertson JI, Nicholls MG (Eds). Mosby, London, UK (1993).
3. Dzau VJ. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37(4), 1047-1052 (2001).
4. Borghi C, Bacchelli S, Ambrosioni E. The use of zofenopril and fosinopril in acute myocardial infarction and carotid artery disease. Am. J. Hypertens. 7(9 Pt 2), S96-S101 (1994).
5. Braunwald E, Domanski MJ, Fowler SE et al.; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351(20), 2058-2068 (2004).
6. Flather MD, Yusuf S, Køber L et al.; ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACEinhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355(9215), 1575-1581 (2000).
7. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342(3), 145-153 (2000).
8. Cushman DW, Wang FL, Fung WC et al. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 28(Suppl. 2), S115-S130; discussion S130 (1989).
9. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc. Drug Rev. 17, 115-133 (1999).
10. Ranadive SA, Chen AX, Serajuddin AT. Relative lipophilicities and structural- pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res. 9(11), 1480-1486 (1992).
11. Grover GJ, Sleph PG, Dzwonczyk S et al. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection. J. Pharmacol. Exp. Ther. 257(3), 919-929 (1991).
12. Sargent CA, Sleph PG, Dzwonczyk S et al. Cardioprotection in ischemic rat hearts with the SH-containing angiotensinconverting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel. J. Pharmacol. Exp. Ther. 265(2), 609-618 (1993).
13. Liu X, Engelman RM, Rousou JA, Cordis GA, Das DK. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc. Drugs Ther. 6(4), 437-443 (1992).
14. Ferrari R, Cargnoni A, Curello S, Ceconi C, Boraso A, Visioli O. Protection of the ischemic myocardium by the convertingenzyme inhibitor zofenopril: insight into its mechanism of action. J. Cardiovasc. Pharmacol. 20(5), 694-704 (1992).
15. Przyklenk K, Kloner RA. 'Cardioprotection' by ACE-inhibitors in acute myocardial ischemia and infarction?. Basic Res. Cardiol. 88(Suppl. 1), 139-154 (1993).
16. Przyklenk K, Kloner RA. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am. Heart J. 121(5), 1319-1330 (1991).
17. Westlin W, Mullane K. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?. Circulation 77(6 Pt 2), I30-I39 (1988).
18. de Nigris F, D'Armiento FP, Somma P et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidationspecific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int. J. Cardiol. 81(2-3), 107-115; discusssion 115 (2001).
19. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic review of individual data from 100,000 patients in randomized trials. Circulation 97, 2202-2212 (1998).
20. Latini R, Tognoni G, Maggioni AP et al.; Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. Clinical effects of early angiotensin-converting enzyme inhibitortreatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. J. Am. Coll. Cardiol. 35(7), 1801-1807 (2000).
21. Ambrosioni E, Borghi C, Magnani B. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. SMILE pilot study working party. Am. J. Cardiol. 68(14), D101-D110 (1991).
22. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin- convertingenzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N. Engl. J. Med. 332(2), 80-85 (1995).
23. Gruppo Italiano per la Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343, 1115-1122 (1994).
24. ISIS Collaborative Group. ISIS-4: randomised study of oral captopril in over 50,000 patients with suspected acute myocardial infarction. Circulation 88(Suppl. I), I-394 (1993).
25. Borghi C, Ambrosioni E, Magnani B. Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of myocardial infarction long-term evaluation. Am. J. Cardiol. 78(3), 317-322 (1996).
26. Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am. J. Hypertens. 12(7), 665-672 (1999).
27. Nesto RW, Zarich S. Acute myocardial infarction in diabetes mellitus: lessons learned from ACE inhibition. Circulation 97(1), 12-15 (1998).
28. Borghi C, Bacchelli S, Esposti DD, Ambrosioni E; SMILE Study. Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care 26(6), 1862-1868 (2003).
29. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in Type 2 diabetes. N. Engl. J. Med. 359, 1565-1576 (2008).
30. Borghi C, Cicero AF, Bacchelli S, Esposti DD, Ambrosioni E; Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. Fundam. Clin. Pharmacol. 23(5), 641-648 (2009).
31. Borghi C, Cicero AF, Ambrosioni E. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc. Health Risk Manag. 4(3), 665-671 (2008).
32. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 105(3), 393-396 (2002).
33. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E; Survival of Myocardial Infarction Long-Term Evaluation Study. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction. Am. Heart J. 152(3), 470-477 (2006).
34. Borghi C, Ambrosioni E; Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)- ISCHEMIA study. Am. Heart J. 153(3), 445.e7-445.e14 (2007).
35. Borghi C, Ambrosioni E; Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am. Heart J. 145(1), 80-87 (2003).
36. Jhund P, McMurray JJ. Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor?. Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. Circulation 113(22), 2566-2568 (2006).
37. Borghi C, Ambrosioni E. Double-blind, randomized comparison of zofenopril vs. ramipril in MI patients treated with ASA: the SMILE 4 Study and Subgroup Analysis. SMILE Study Investigators. Circulation 124, A14717 (2011).